沙库巴曲缬沙坦治疗射血分数下降慢性心力衰竭的临床研究

Clinical study of sakubactrovalsartan in the treatment of chronic heart failure with decreased Ejection fraction

目的:观察沙库巴曲缬沙坦治疗射血分数下降慢性心力衰竭的临床疗效。方法:选取2022年1月至2023年2月在本院就诊的83例射血分数下降的慢性心力衰竭患者,作为本次研究对象,回顾性分析所有患者临床资料,按照治疗方案不同分为对照组(贝那普利治疗)41例和观察组(沙库巴曲缬沙坦治疗)42例。治疗6 m后,按照《2021欧洲心脏病学会急性心力衰竭指南解读》进行临床疗效判定比较两组临床疗效、采用彩色多普勒超声评估心脏功能,如左室射血分数(Left ventricular ejection fraction,LVEF)、左室舒张末内径(Left ventricular end diastolic diameter,LVDd)及收缩末内径(Left ventricular end-systolic diameter,LVDs)值,记录用药期间不良反应等。结果:两组经过治疗后,观察组治疗有效率(95.24%)高于对照组(78.05%),(P<0.05)。两组治疗后LVEF均升高、LVDd及LVDs均下降,观察组LVEF高于对照组、LVDs低于对照组,(P<0.05);但比较两组LVDd,差异无统计学意义(P>0.05)。对照组不良反应率为14.63%,观察组不良反应率为19.05%,差异无统计学意义(P>0.05)。结论:沙库巴曲缬沙坦治疗射血分数下降慢性心力衰竭患者有较好疗效,可提升LVEF及改善LVDs水平,且安全性较高,值得临床采用。

Objective:To observe the clinical efficacy of Valsartan in the treatment of chronic heart failure with decreased Ejection fraction.Methods:83 patients with chronic heart failure with decreased ejection fraction who were treated in our hospital from January 2022 to February 2023 were selected,and were set as the subjects of this study,the clinical data of all patients were retrospectively analyzed,and according to different treatment plans,they were divided into the control group(Benazepril treatment)with 41 cases and observation group(Sacubatravalsartan treatment)with 42 cases.After 6 months of treatment,according to the Interpretation of the 2021 European Society of Cardiology Guidelines for Acute Heart Failure,the clinical efficacy of the two groups was compared,and the left ventricular ejection fraction,left ventricular ejection fraction,color Doppler ultrasound was used to evaluate cardiac function:left ventricular ejection fraction(LVEF),Left ventricular end diastolic diameter(LVDd)and Left ventricular end diastolic diameter(LVDs),adverse reactions were recorded during medication.Results:After treatment in the two groups,the effective rate of the observation group(95.24%)was higher than that of the control group(78.05%)(P<0.05).After treatment,LVEF in the two groups increased,LVDd and LVDs decreased,and LVEF in the observation group was higher than that in the control group,and LVDs in the observation group was lower than that in the control group(P<0.05);but there was no significant difference in LVDd between the two groups(P>0.05).The adverse reaction rate was 14.63%in the control group,and the adverse reaction rate was 19.05%in the observation group,and the difference was not statistically significant(P>0.05).Conclusion:Sacubitril-valsartan has a good curative effect in the treatment of patients with chronic heart failure with decreased ejection fraction,can increase LVEF and improve the level of LVDs,and has high safety,which is worthy of clinical application.